Literature DB >> 3783190

Immunological relationship between a demyelinating RNA enveloped budding virus (Semliki Forest) and brain glycolipids.

A Khalili-Shirazi, N Gregson, H E Webb.   

Abstract

A monoclonal antibody (MAb) raised against central nervous system (CNS) myelin (212) and a MAb (308) raised against brain with Semliki Forest virus (SFV) were both found to react against the same CNS glycolipids. Both these MAbs were also found to react strongly with SFV and against certain brain glycolipid fractions in an immunosorbent assay (ELISA). This demonstrates the presence of common glycolipid antigens in the viral envelope and CNS myelin. MAb 212 had no SFV neutralising capacity and that of MAb 308 was not significant. However, MAb 212 inhibited the neutralisation of the virus by the MAbs (302, 307) specific to SFV proteins. The implications of these findings in relation to the viral induced CNS autoimmunity and persistence of virus in the CNS is discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3783190     DOI: 10.1016/0022-510x(86)90144-9

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

1.  CNS pathogenesis following a dual viral infection with Semliki Forest (alphavirus) and Langat (flavivirus).

Authors:  S Amor; H E Webb
Journal:  Br J Exp Pathol       Date:  1988-04

Review 2.  Can antiglycolipid antibodies present in HIV-infected individuals induce immune demyelination?

Authors:  S Petratos; M E Gonzales
Journal:  Neuropathology       Date:  2000-12       Impact factor: 1.906

Review 3.  Do human T-lymphotrophic viruses (HTLVs) and other enveloped viruses induce autoimmunity in multiple sclerosis?

Authors:  A G Dalgleish; J K Fazakerley; H E Webb
Journal:  Neuropathol Appl Neurobiol       Date:  1987 Jul-Aug       Impact factor: 8.090

Review 4.  Pathogenesis of virus-induced demyelination.

Authors:  J K Fazakerley; M J Buchmeier
Journal:  Adv Virus Res       Date:  1993       Impact factor: 9.937

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.